UROMUNE™ (MV 140) is a new vaccine for the prevention of uncomplicated recurrent urinary tract infections (rUTI) in women.
UTIs are one of the most common infections in Canada. More than 50% of women experience a Urinary Tract Infection (UTI) in their lifetime , with 20% to 40% of those developing recurrent UTIs requiring multiple short and long-term dosing of antibiotics. Recurrent UTIs (rUTIs) are defined as three or more UTIs during a 12-month period.
UROMUNE™ is currently available through various special access programs in countries around the world, including the UK, the Netherlands, Sweden, Norway, Spain, Australia and New Zealand. More than 40,000 patients have used UROMUNE™ to date and a Phase III European randomized control clinical trial has been completed.
UROMUNE™ was developed by Inmunotek, an innovative pharmaceutical company based in Spain. The product is exclusively licensed in Canada to Red Leaf Medical. The company intends to file a new drug submission for UROMUNE™ with Health Canada in Q4 2021.